Soleus Capital Management L.P. Sells 49,500 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Soleus Capital Management L.P. trimmed its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 52.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,500 shares of the company’s stock after selling 49,500 shares during the quarter. Soleus Capital Management L.P. owned 0.06% of Viridian Therapeutics worth $872,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. R Squared Ltd bought a new stake in shares of Viridian Therapeutics in the 4th quarter valued at $26,000. Foresite Capital Management VI LLC acquired a new position in Viridian Therapeutics in the fourth quarter valued at about $38,000. AlphaQuest LLC increased its holdings in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock worth $54,000 after acquiring an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after purchasing an additional 1,516 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Viridian Therapeutics during the fourth quarter worth about $164,000.

Analysts Set New Price Targets

A number of research firms recently issued reports on VRDN. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. JMP Securities cut their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reduced their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Royal Bank of Canada lowered their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $36.70.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $12.94 on Monday. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -3.00 and a beta of 0.57. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The firm has a fifty day simple moving average of $13.41 and a 200 day simple moving average of $17.10. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Viridian Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. Research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.